Artivion/$AORT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
- Ticker
- $AORT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,800
- Headquarters
- Kennesaw, United States
- Website
- artivion.com
Artivion Metrics
BasicAdvanced
$932M
-
-$0.37
1.28
-
Price and volume
Market cap
$932M
Beta
1.28
52-week high
$48.25
52-week low
$18.95
Average daily volume
709K
Financial strength
Current ratio
4.42
Quick ratio
2.019
Long term debt to equity
0.898
Total debt to equity
0.912
Interest coverage (TTM)
1.36%
Profitability
EBITDA (TTM)
55.557
Gross margin (TTM)
63.31%
Net profit margin (TTM)
-3.65%
Operating margin (TTM)
6.09%
Effective tax rate (TTM)
-63.76%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
2.40%
Return on equity (TTM)
-3.98%
Valuation
Price to revenue (TTM)
1.911
Price to book
2.09
Price to tangible book (TTM)
-7.74
Price to free cash flow (TTM)
-17.582
Free cash flow yield (TTM)
-5.69%
Free cash flow per share (TTM)
-1.086
Growth
Revenue change (TTM)
14.01%
Earnings per share change (TTM)
76.51%
3-year revenue growth (CAGR)
12.36%
10-year revenue growth (CAGR)
10.65%
3-year earnings per share growth (CAGR)
-15.36%
10-year earnings per share growth (CAGR)
1.07%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Analyst projections of the future price of Artivion stock.
Bulls say / Bears say
Third-quarter revenue rose 9% on a constant-currency basis to $123.8 million, with stent grafts up 12% and On-X up 13%. Its two main product growth engines are still delivering. (Artivion)
The acquired, FDA-approved NEXUS system adds another aortic-arch product, with a US launch planned for January 2027. Artivion says the platform also supports three further PMA programmes in development. (Artivion, The Motley Fool)
Profitability and cash flow weakened even as sales grew: third-quarter adjusted EBITDA fell 8%, gross margin declined to 61.4% from 65.6%, and free cash flow was negative $17.6 million. Net debt of $363.8 million and leverage of 3.5 times add pressure while the company invests in production and launches. (The Motley Fool)
The PerClot supply agreement is due to end in February 2027, removing about $10 million of revenue and creating expected headwinds of 2 percentage points to revenue growth and 4 points to EBITDA growth. Management expects the combined business to be EBITDA neutral in 2027 as NEXUS sales build. (The Motley Fool)
AMDS adoption still faces hospital purchasing friction: starter sets require an upfront investment of about $100,000, and US set sales remained challenged in the third quarter. That could slow uptake despite the removal of the IRB hurdle. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Artivion News
AllArticlesVideos
Funds containing Artivion
Fund name | Fund size | $AORT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.06% |
iShares S&P Small Cap 600£ISP6 | $2.5B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.03% |
iShares MSCI World Small Cap€IUSN | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.